MP29-02: formulation of azelastine and fluticasone propionate [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 9897697 |
| MeSH ID | M0575703 |
| Synonym |
|---|
| azelastine hydrochloride/fluticasone propionate |
| mp 29-02 |
| azelastine / fluticasone propionate |
| 1417803-89-4 |
| azelastine hydrochloride / fluticasone propionate |
| dymista |
| mp29-02 |
| DTXSID40161821 |
| 4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)phthalazin-1-one;[(6s,8s,9r,10s,11s,13s,14s,16r,17r)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propano |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The incidence of treatment-related adverse events was low with both MP29-02 (9." | ( Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis. Berger, WE; Bhatia, S; Hadley, J; Lieberman, P; Munzel, U; Price, D; Shah, S, ) | 0.64 |
The paper provides for the first time information on potential drug-drug interactions, AZE and FP bioavailability and disposition characteristics of each component. Azelastine bioavailability was similar for MP29-02 and Astelin®.
| Excerpt | Reference | Relevance |
|---|---|---|
| " • For new combination medicinal products such as MP29-02, the determination of possible pharmacokinetic (PK) drug-drug interactions between both active components and formulation-based bioavailability alterations is essential." | ( Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray. Bousquet, J; Derendorf, H; Hermann, R; Mascher, H; Maus, J; Munzel, U; Petzold, U, 2012) | 0.85 |
| "• This paper provides for the first time information on potential drug-drug interactions, AZE and FP bioavailability and disposition characteristics of each component administered by the novel nasal spray formulation MP29-02." | ( Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray. Bousquet, J; Derendorf, H; Hermann, R; Mascher, H; Maus, J; Munzel, U; Petzold, U, 2012) | 0.79 |
| " Azelastine bioavailability was similar for MP29-02 and Astelin®." | ( Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray. Bousquet, J; Derendorf, H; Hermann, R; Mascher, H; Maus, J; Munzel, U; Petzold, U, 2012) | 0.86 |
| " Here we review all the safety information relevant to MP29-02, from the initial phase I bioavailability and disposition data, to the phase III 14-day and 52-week data and finally to phase IV safety data collected during MP29-02 use in routine clinical practice." | ( Safety evaluation of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) for allergic rhinitis. Bousquet, J; Klimek, L; Price, D, 2016) | 1 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 12 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (16.46) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 7 (46.67%) | 5.53% |
| Reviews | 6 (40.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 2 (13.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||